65 completed, 20 terminated, 4 recruiting, 3 withdrawn. 48 Phase 1, 45 Phase 2, 11 Not applicable, 3 Phase 4, 2 Early Phase 1.
Follow Waldenström Macroglobulinemia: new trials by email Literature Review of Waldenström Macroglobulinemia trials Research Report on Waldenström Macroglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia Pacritinib - Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Recruiting | Shayna Sarosiek, MD | 30 | 2025-11-21 | 2025-12-05 |
| Preliminary Assessment of [18F]BL40 in PET/CT Scans 18F-BL40 PET/CT, 18F-FDG PET/CT, Routine Blood Draw - Phase 1 only - Diffuse Large B-cell Lymphoma, Multiple Myeloma | Recruiting | British Columbia Cancer Agency | 30 | 2024-06-10 | 2026-10-01 | |
| Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader Tacabrutideg - B-cell Malignancy, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 146 | 2022-05-06 | 2026-10-21 |
| A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies Tacabrutideg - B-cell Malignancy, Marginal Zone Lymphoma | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 689 | 2021-09-13 | 2026-10-05 |
| Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia Zanubrutinib,Ixazomib and Dexamethasone - Waldenström Macroglobulinemia | Phase 2 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 25 | 2020-06-01 | 2026-02-11 |
| A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia Daratumumab - Waldenström Macroglobulinemia | Phase 2 | Completed | Dana-Farber Cancer Institute | 13 | 2017-11-27 | 2022-11-23 |
| BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia BI-1206 single agent dose escalation phase, Combination of BI-1206 with rituximab escalation phase, BI-1206 single agent expansion phase - B-cell Lymphoma, Chronic Lymphocytic Leukaemia | Phase 1 / Phase 2 | Completed | Cancer Research UK | 14 | 2016-10-27 | 2021-07-08 |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia autologous stem cell transplantation, conventional chemotherapy - Waldenström Macroglobulinemia | Phase 4 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 70 | 2016-05-01 | 2026-02-11 |
| The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Bortezomib, Rituximab - Waldenström Macroglobulinemia | Phase 4 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 35 | 2016-05-01 | 2026-02-11 |
| The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Thalidomide - Waldenström Macroglobulinemia | Phase 4 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 44 | 2016-05-01 | 2026-02-11 |
| Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia Blood or bone marrow samples - Waldenström Macroglobulinemia | Not applicable | Completed | Central Hospital, Nancy, France | 55 | 2016-02-01 | 2021-08-06 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Acalabrutinib, Pembrolizumab - Follicular Lymphoma (FL), CLL | Phase 1 / Phase 2 | Completed | Acerta Pharma BV | 161 | 2015-02-20 | 2026-05-13 |
| Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma carmustine, cytarabine, melphalan - Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma | Not applicable | Withdrawn | Fred Hutchinson Cancer Center | 2015-02-01 | 2015-05-07 | |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma PI3K inhibitor BKM120, rituximab, Pharmacodynamics - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 | Completed | Kami Maddocks, MD | 18 | 2014-07-21 | 2022-06-30 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant busulfan, etoposide, cyclophosphamide - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Early Phase 1 | Completed | Case Comprehensive Cancer Center | 33 | 2014-03-01 | 2015-08-13 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
Showing 20 of 94. Sign in to see all of them.
Waldenstrom Macroglobulinemia (94) · Lymphoma, B-Cell, Marginal Zone (81) · Lymphoma, Follicular (78) · Leukemia, Lymphocytic, Chronic, B-Cell (75) · Lymphoma, Mantle-Cell (73) · Lymphoma, Large B-Cell, Diffuse (70) · Lymphoma, Non-Hodgkin (66) · Burkitt Lymphoma (62) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (62) · Lymphoma, Large-Cell, Immunoblastic (57) · Hodgkin Disease (47) · Mycosis Fungoides (47) · Sezary Syndrome (47) · Lymphoma, T-Cell, Cutaneous (45) · Lymphoma, Large-Cell, Anaplastic (44)
Blood Protein Disorders (94) · Cardiovascular Diseases (94) · Hematologic Diseases (94) · Hemic and Lymphatic Diseases (94) · Hemorrhagic Disorders (94) · Hemostatic Disorders (94) · Immune System Diseases (94) · Immunoproliferative Disorders (94) · Lymphatic Diseases (94) · Lymphoproliferative Disorders (94) · Neoplasms by Histologic Type (94) · Paraproteinemias (94) · Vascular Diseases (94) · Neoplasms (93) · Neoplasms, Plasma Cell (92)
Peripheral Blood Stem Cell Transplantation (20) · Rituximab (20) · fludarabine phosphate (19) · Whole-Body Irradiation (17) · Mycophenolic Acid (14) · Cyclophosphamide (12) · Cyclosporine (11) · Bortezomib (8) · Etoposide (8) · Tacrolimus (6) · Busulfan (5) · Filgrastim (5) · Granulocyte Colony-Stimulating Factor (5) · Indium (4) · Transplantation (4)
National Cancer Institute (NCI) (37) · Fred Hutchinson Cancer Center (19) · Institute of Hematology & Blood Diseases Hospital, China (4) · Case Comprehensive Cancer Center (3) · Roswell Park Cancer Institute (3) · BeOne Medicines (2) · City of Hope Medical Center (2) · Mayo Clinic (2) · University of Chicago (2) · University of Washington (2) · Acerta Pharma BV (1) · Barbara Ann Karmanos Cancer Institute (1) · BeiGene (1) · British Columbia Cancer Agency (1) · Cancer Research UK (1)
United States (84) · Italy (8) · China (6) · Germany (5) · Canada (4) · France (3) · United Kingdom (2) · Australia (1) · Brazil (1) · Georgia (1) · Japan (1) · Moldova (1) · South Korea (1) · Spain (1) · Sweden (1)
Ajay Gopal (6) · David Maloney (5) · Brenda Sandmaier (4) · Shuhua Yi, Doc (3) · Anas Younes (2) · Ann Woolfrey (2) · John Byrd (2) · Patricia LoRusso (2) · Sonali Smith (2) · Thomas Witzig (2) · Adam Petrich, MD (1) · Andre Goy (1) · Andrew Davies, Prof (1) · Antonius Miller (1)
PMID 32499241, PMID 18698002, PMID 19826119, PMID 19900571, PMID 20837940, PMID 21072184, PMID 21508413, PMID 22259028, PMID 22289993, PMID 22308288, PMID 23065509, PMID 23233721, PMID 23256542, PMID 24241210, PMID 24474568, PMID 24530971, PMID 24990615, PMID 26213141, PMID 26764356, PMID 26853648, PMID 27118452, PMID 29292843, PMID 30454872, PMID 30562587, PMID 31388792, PMID 31481800, PMID 34515338, PMID 38205507, PMID 40720747
P30CA015704 (14), P01CA018029 (5), U01CA062487 (5), U01CA062491 (5), U01CA076576 (5), P30CA015083 (4), U01CA062502 (4), U01CA099168 (4), N01CM17003 (3), N01CM62202 (3), P01CA044991 (3), P01CA078902 (3), U01CA062505 (3), U01CA069912 (3), P30CA014599 (2)